- Lobbying
- Sarah AND D'Orsie
Lobbying Arrangements Results for 'Sarah D'orsie'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Pharmaceutical supply chain and API procurement, Global drug shortages, Tax reform Rebate reform, any willing pharmacy, PBMs, IRA Medicare Direct Negotiation, DIR fees IRA, Part D redesign, rebates... |
Fresenius Kabi USA LLC
|
in-house lobbying | |||
Details H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 19, S. 2164, Lower Costs, More Cures Act of 2021. H.R. 5376, Build Back Better Act, specifically issues dealing with Medicare. H.R.7667 - F... |
Avanir Pharmaceuticals
|
in-house lobbying | |||
Details COVID-19 Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Streamlining access to rehabilitation for Medicare beneficiaries (SNF three day rule, IRF three hour rule, prior authorization) Funds for... |
American Academy of Physical Medicine and Rehabilitation
|
in-house lobbying | |||
Details Funding of TBI Act & CDC TBI programs as well as funding for TBI Model Systems |
Brain Injury Association of America (fka Brain Injury Association)
|
in-house lobbying | |||
Details Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation... |
Astellas Pharma US, Inc.
|
in-house lobbying | |||
Details Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan cover... |
BIOGEN
|
in-house lobbying |